No: PRP injections do not reliably regrow cartilage in human joints. At best, current trials show small, temporary improvements in pain and function, plus biochemical signals that may calm synovitis and transiently favor chondrocyte activity. They do not restore hyaline cartilage volume in knees, hips, or small joints. The question of can PRP injections regrow cartilage? depends on the outcome: symptom scores can improve by roughly 10 to 20 points on a 100-point scale at 3 to 6 months, while MRI cartilage thickness usually changes by less than 0.2 mm, near measurement error. Evidence remains moderate at best and inconsistent across joints.
How PRP Acts on the Joint, Not Just the Cartilage
PRP is an autologous blood concentrate with a platelet count usually 2 to 5 times that of peripheral blood. Platelets release alpha-granule factors such as TGF-beta1, PDGF, IGF-1, and VEGF within minutes to hours. These factors can stimulate chondrocyte migration and matrix synthesis in laboratory dishes. They also affect synovial macrophages and inflammatory signaling in living joints.
The cartilage problem is access and durability. Mature hyaline cartilage is avascular, sparsely cellular, and only 2 to 4 mm thick in the knee. PRP does not contain stem cells, does not provide a structural scaffold, and does not stay in the joint for long. Much of the injected volume leaves or is cleared within 24 to 72 hours, although growth factors can bind locally for somewhat longer.
The most plausible clinical mechanism is not direct regrowth. PRP appears to modulate synovitis, reduce catabolic cytokines such as IL-1 beta and TNF-alpha, and temporarily shift pain signaling. In plain terms: PRP may calm the joint lining and reduce pain chemistry, but it does not reliably build a new cartilage layer. That distinction separates symptom relief from tissue regeneration.
Established science supports a modest anti-inflammatory and symptom-modifying effect in some knee osteoarthritis patients. The hypothesis that PRP can produce durable hyaline cartilage regrowth remains unproven in humans. Any claim of regrowth must survive imaging resolution, histology, and long-term durability checks.
Can PRP Injections Regrow Cartilage? What Trials Actually Measure
Most trials measure symptoms, not cartilage. The common primary outcome is the WOMAC scale, which runs from 0 to 100 and combines pain, stiffness, and function. A 10-point improvement is often used as the minimal clinically important difference. MRI cartilage thickness changes of 0.1 to 0.3 mm are near the measurement error of standard scans.
For context, a 10-point WOMAC improvement is often used as the minimal clinically important difference, and a 0.2-mm MRI cartilage change sits near the typical 0.1-0.3 mm measurement error; these thresholds use different scales, so a symptom responder is not a cartilage responder. That single distinction explains most conflicting headlines. A trial can report a real symptom benefit without showing any cartilage regrowth.
The table below compares typical ranges from randomized and quasi-randomized knee osteoarthritis studies. These are approximate ranges, not guarantees for an individual joint. Product preparation and patient selection vary widely.
| Treatment | Typical 0-100 WOMAC improvement at 3-6 months | MRI cartilage change at 12 months | Typical duration | Main trade-off |
|---|---|---|---|---|
| PRP | 10-20 points | -0.1 to +0.1 mm, within error | 6-12 months, then fades | Variable product; cost often USD 200 to USD 1,200 per injection; no regeneration approval |
| Hyaluronic acid | 8-15 points | -0.1 to +0.05 mm | 3-6 months | Lower cost; repeat injections needed; lubricant not repair |
| Corticosteroid | 15-25 points early | -0.1 to +0.05 mm; possible slight loss with repeated use | 4-12 weeks | Fast but short; repeated use may accelerate cartilage loss |
| Saline | 5-10 points | -0.1 mm or no change | 1-3 months | Placebo and injection context; no repair |
A non-obvious comparison is timing. Corticosteroid often beats PRP at 2 to 6 weeks, with a 15-25 point WOMAC advantage early. By 6 to 12 months, PRP may show a 5-10 point advantage over corticosteroid in some meta-analyses. That late advantage is inconsistent and does not equal cartilage regrowth.
Imaging tells a more conservative story. Most randomized MRI studies show no significant cartilage thickness gain, and some show continued age-related loss. A few small studies report less cartilage loss in PRP arms, but the differences are often 0.1 mm or less. That magnitude is close to scan variability and cannot be called regrowth.
Timeline: When Symptom Relief Appears and Fades
PRP has a predictable symptom arc in responders, but not a cartilage-building arc. The timeline below reflects typical trial patterns and clinical experience. Individual responses range from no effect to 20-point or larger symptom changes.
| Time after injection | What happens biologically | What imaging shows | Practical meaning |
|---|---|---|---|
| Day 0 | Platelets degranulate within minutes; growth factors enter synovial fluid | No visible change | Injection day is not a regeneration event |
| Days 1-3 | Mild inflammatory response; soreness and swelling can occur | No change | Ice and relative rest may help; severe pain is not expected |
| Week 1-2 | Cytokine shift and macrophage modulation begin | No change | Early pain relief is variable and partly placebo |
| Week 4-6 | Responders often improve by 8-15 WOMAC points | Cartilage thickness change usually below 0.1 mm | First fair checkpoint for symptom response |
| Month 3 | Peak average symptom benefit, often 10-20 points | Still within 0.1 mm in most studies | Reassess function and pain, not MRI “regrowth” |
| Month 6 | Benefit plateaus or fades in many patients | No consistent thickness gain | Repeat injection decisions should be conservative |
| Month 12 | Mean improvement often 5-12 points if present | -0.1 to +0.1 mm typical | Durable cartilage change is not established |
| Month 18-24 | Most symptom scores drift toward baseline | Continued loss or no change | Long-term regrowth claims remain unsupported |
The key clinical lesson is that the symptom peak comes before any plausible tissue-change window. If a clinic claims visible cartilage regrowth at 6 weeks, the claim likely reflects MRI noise, contrast effects, or slice-position differences. Cartilage is slow, and PRP is fast-clearing.
Joint-by-Joint Variation: Knee, Hip, and Small Joints
The knee is the best-studied joint. It accounts for roughly 60 to 70 percent of PRP osteoarthritis trials. Patients with Kellgren-Lawrence grade 1 to 3 disease and BMI under 30 often show the largest symptom responses. In many knee trials, 55 to 70 percent of patients cross a 10-point WOMAC responder threshold at 3 to 6 months.
The hip has weaker evidence. Hip trials are fewer, usually smaller, and often include 20 to 60 patients. Reported responder rates are commonly 40 to 55 percent, and rapid hip progression can confound results. Image guidance matters because the hip is deep and inaccurate injection can miss the joint.
Small joints such as the thumb carpometacarpal joint have early, low-power evidence. Series often include 10 to 30 patients and report 40 to 60 percent pain improvement at 3 months. These numbers sound promising, but small samples inflate apparent effects. Steroid injection remains a common comparator for thumb-base arthritis.
Focal cartilage defects are a separate case. PRP is sometimes used as an adjunct to microfracture or other marrow-stimulation surgery. Small trials suggest 8 to 12 point KOOS improvements when PRP is added, but defect fill on MRI is inconsistent. PRP alone is not a stand-alone defect-repair technique.
Misconceptions and Red Flags
PRP is not a stem-cell therapy. It contains platelets, plasma, and variable leukocytes, but no meaningful population of cartilage-forming stem cells. Clinics that combine PRP with unverified “stem cell” claims are selling a different product with different regulatory and safety questions.
More platelets are not always better. Leukocyte-rich PRP can increase inflammatory cytokines in some laboratory models, while leukocyte-poor PRP may be preferable for knee osteoarthritis. The evidence is not definitive, but the “more concentrated is better” assumption is too simple.
MRI “regrowth” is often measurement noise. A 0.1 to 0.2 mm change can come from slice angle, joint position, cartilage contrast, or reader variability. Without histology, no imaging study can prove new hyaline cartilage rather than scar, fibrocartilage, or edema change.
Seek urgent care for these red flags after any joint injection:
- Fever above 101°F, chills, spreading redness, or warmth at the injection site.
- Severe joint pain or swelling that worsens after 48 hours instead of settling.
- Calf swelling, chest pain, or shortness of breath after hip or knee injection.
- New numbness, weakness, or loss of range of motion.
- A clinic promising guaranteed cartilage regrowth or using unverified “stem cell” marketing.
What to Actually Do Before and After PRP
Before asking can PRP injections regrow cartilage in your own joint, confirm the diagnosis. Plain radiographs show joint space and alignment, while MRI is useful when mechanical symptoms, ligament injury, or focal defects are suspected. PRP is a poor first choice for a locked knee, unstable ligament, or advanced bone-on-bone arthritis.
Start with core care. The 2019 OARSI guidelines place exercise and weight management at the center of knee osteoarthritis care. A 5 to 10 percent body-weight loss can reduce knee load and pain. Twelve weeks of supervised strength and neuromuscular training is a reasonable first trial before injection.
If PRP is still considered, ask for product details. Request platelet count, leukocyte content, activation method, injection volume, and whether ultrasound guidance is used. A typical course uses 1 to 3 injections spaced 1 to 3 weeks apart, but the optimal schedule is not established. Cost often ranges from USD 200 to USD 1,200 per injection and is usually out of pocket.
Set a fair reassessment point. At 3 months, compare pain and function with baseline using a 0-100 scale. A change below 8 to 10 points is unlikely to feel meaningful. If there is no meaningful response by 3 months, repeating PRP is unlikely to create cartilage regrowth and should not be sold as such.
Limits of the Evidence and the Realistic Ceiling
The evidence base has three hard limits. First, PRP products are not standardized, so platelet dose, leukocyte content, and activation differ across trials. Second, most studies are small and follow patients for only 6 to 12 months. Third, few human studies include histology, so claims about hyaline cartilage regrowth rest on imaging surrogates.
The FDA has not approved PRP as a cartilage-regenerating biologic; when prepared and used in the same procedure, it is regulated as an autologous blood product under tissue rules updated in 2020. That regulatory status does not prove ineffectiveness for symptoms. It does mean “regrow cartilage” is a marketing claim, not an approved indication.
Long-term data remain thin. Fewer than 10 percent of PRP osteoarthritis trials report 24-month imaging outcomes, and almost none report 5-year structural endpoints. The realistic ceiling is modest symptom improvement in selected patients, with possible reduction in synovitis. Can PRP injections regrow cartilage? For now, the answer is no for durable hyaline regeneration and a qualified maybe for temporary symptom relief.